Aerska: Funding, Investors & Team (Sep 2026)
Aerska is a biotechnology company that is creating RNA medications to treat, postpone, and prevent brain disorders.
Aerska has raised $60.0M across 2 funding rounds on record, the most recent a Series A of $39.0M announced in Feb 2026.
That round is in line with the $42M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Aerska Company Profile and Key Stats
Latest funding round on record: Feb 2026.
Aerska Funding Rounds
Aerska raised $21.0M in a Seed announced in Sep 2025.
5 months later, a Series A of $39.0M was announced in Feb 2026.
Aerska Founders and Leadership Team
Contact details for the Aerska team: 1 of 2 have an email address on file, 1 has a LinkedIn profile.
Start 14-day free trial →Aerska Funding Compared to Other Biotechnology Startups
Aerska's latest round of $39.0M is in line with the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Biotechnology Startups Like Aerska
Companies Similar to Aerska
Crystalys Therapeutics is a clinical-stage biopharmaceutical company transforming the treatment of gout.
Weike Bio is a gene therapy drug development company.
Twinpig Biolab researches and develops anticancer drugs.
Kunshi Biotechnology is a drug developer with an emphasis on solid tumor cells.
Lifordi Immunotherapeutics is a biotech company that provides antibody-drug conjugates for autoimmune and…
Solve Therapeutics is a biopharmaceutical company that develops Antibody Drug Conjugate and Bispecific…
Artizan Biosciences focuses on drug discovery and development for diseases involving the human intestinal…
Neok Bio is a biotech startup that focuses on bispecific ADCs in cancer therapy.
BOOST Pharma develops a stem cell therapy for the treatment of osteogenesis imperfecta.
Step Pharma is a biotechnology company.
TORL BioTherapeutics is a clinical-stage biopharmaceutical business.
ThirdLaw Molecular pioneers revolutionary Spiroligomer™ molecules for safer, more targeted, effective disease…
Aerska Funding FAQs
What does Aerska do?
Aerska is a biotechnology company that is creating RNA medications to treat, postpone, and prevent brain disorders.
How much funding has Aerska raised?
Aerska has raised $60.0M across 2 rounds on record. The most recent is a Series A of $39.0M announced in Feb 2026.
When did Aerska last raise funding?
Aerska's most recent funding round on record is a Series A of $39.0M, announced in Feb 2026.
Who founded Aerska?
FundedIQ lists David Hardwicke (Founder) at Aerska.
Who is the CEO of Aerska?
Jack O'Meara is listed as CEO at Aerska.
How many employees does Aerska have?
Aerska is in the 11-50 employee band.
How does Aerska's funding compare to other Biotechnology startups?
Aerska's latest round of $39.0M is in line with the $42M median round size for Biotechnology companies on FundedIQ across 20 tracked companies over the last two years.
About FundedIQ's Aerska Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Aerska is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.